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http://dx.doi.org/10.1016/j.jfma.201Background/purpose: Sentinel lymph node biopsy (SLNB) is a standard procedure in the man-
agement of clinically node-negative melanoma. However, few studies have been performed on
SLNB in Asia, which is an acral melanoma-prevalent area. This study evaluated the clinicopath-
ologic prognostic factors of disease-free survival (DFS) and overall survival (OS) in Taiwanese
patients with cutaneous melanoma who received wide excision and SLNB. The prognosis of
patients with false-negative (FN) SLNB was also evaluated.
Methods: Malignant melanoma cases were reviewed for 518 patients who were treated be-
tween January 2000 and December 2011. Of these patients, 127 patients with node-negative
cutaneous melanoma who received successful SLNB were eligible for inclusion in the study.ematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou 5,
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416 C.-E. Wu et al.Results: The SLNB-positive rate was 34.6%. The median DFS was 51.5 months, and the median
OS was 90.9 months at the median follow-up of 36.6 months. Multivariate analysis revealed
that patients whose melanoma had a Breslow thickness greater than 2 mm had a significantly
shorter DFS than patients whose melanoma had a Breslow thickness of 2 mm or less [hazard
ratio (HR), 3.421; pZ 0.005]. Independent prognostic factors of OS were a Breslow thickness
greater than 2 mm (HR, 4.435; pZ 0.002); nonacral melanoma (HR, 3.048; pZ 0.001); and an
age older than 65 years (HR, 2.819; p Z 0.036). During the follow-up period, 13 of 83 SLN-
negative patients developed a regional nodal recurrence. The SLNB failure rate was 15.7%
and the FN rate was 22.8%. Compared to patients with a true-positive SLNB, patients with
FN SLNB had a significantly shorter DFS (p Z 0.001) but no significant difference in OS
(p Z 0.262).
Conclusion: Except for the pathologic subtypes, prognostic factors in Taiwan are similar to
those used in other melanoma-prevalent countries. Identifying and closely monitoring pa-
tients at risk of nodal recurrence after a negative SLNB is important.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
In the United States, cutaneous melanoma, the most
serious form of skin cancer, is the fifth most common can-
cer in men and the sixth most common cancer in women.1
Sun exposure is a major risk factor for melanoma.2 Super-
ficial spreading melanoma (SSM) is the most common mel-
anoma subtype in Caucasians. By contrast, cutaneous
melanoma is relatively uncommon in Asians, for whom acral
lentiginous melanoma (ALM) is the most common type of
melanoma.3e6 Acral lentiginous melanoma is deeper in
thickness than other melanoma subtypes, and ALM with a
thickness greater than 4 mm is more common in Asians and
Pacific Islanders than in Caucasians and blacks.7
Sentinel lymph node biopsy (SLNB) was first described in
1992 and has become the standard of care in the treatment
of clinically node-negative melanoma.8,9 However, SLNB is
associated with a risk of a false-negative (FN) SLNB, which
is indicated by a tumor-negative sentinel lymph node (SLN)
with the subsequent development of clinically positive
nodes.10,11 An FN SLNB can have a significant impact on a
patient’s disease-free survival (DFS) outcome.10
Few studies have been performed on SLN (especially FN
SLNB) in Asia, which is an ALM-prevalent area. Because
there are differences between Western and Asian countries
in the prevalence of pathologic melanoma subtypes, we
retrospectively analyzed the clinicopathological prognostic
factors and the results of FN SLNB in Taiwanese patients
with cutaneous melanoma.
Methods
Patients
FromJanuary 1, 2000 toDecember 31, 2011, 518patientswho
had a discharge diagnostic code of melanoma (172.*, V10.82,
M87203-87903)dbased on the ninth revision of
The International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM)dwere treated at the
Chang Gung Memorial Hospital (CGMH) at Linkou in Taiwan.
The records of these patients were reviewed. Patientswho had melanoma in situ, metastatic melanoma, mucosal
melanoma, and ocular melanoma were excluded from the
study. A total of 209 patients had operable cutaneous mela-
noma. Of these patients, the records of 132 patients who had
no clinical evidence of nodal or distant metastasis and who
underwent SLNB were reviewed for clinicopathological fea-
tures and outcomes. None of the patients received adjuvant
high-dose interferon-a. Pathological diagnosis was reviewed
by an experienced pathologist. Staging was determined in
accordance with the American Joint Committee on Cancer
(AJCC) staging system, which was published in 2010.12,13 Pa-
tients diagnosed before 2010 were re-staged by using the
AJCC Cancer Staging Manual (7th edition).13 This study was
approved by the institutional review board of the CGMH.
SLNB
All patients underwent wide local excision (or amputation)
of the primary melanoma and SLNB. An SLN lympho-
scintigraphy was performed immediately after the subder-
mal injection of 1 mL of technetium-99 (1 mCi) sulfur
colloid and vital blue dye. Surgical harvest of the SLN was
performed 2e6 hours after lymphoscintigraphy.14 All
dissected SLNs were cut into serial sections and stained
with hematoxylin and eosin (H&E). Further immunohisto-
chemical staining with HMB-45 was performed if samples
were negative on the H&E-stained sections. A positive SLN
was defined as any sentinel node that exhibited evidence of
metastatic melanoma cells either on H&E-stained sections
or with HMB-45 staining. All patients who had a positive SLN
underwent complete lymph node dissection (CLND).
A true-positive (TP) SLN was defined as a sentinel node
biopsy that contained metastatic melanoma cells. An FN
SLN was defined as an initially negative SLN but the patient
subsequently develops clinically positive nodes within the
mapped basin. A true-negative (TN) SLN was defined an
initially negative SLN but the patient has no evidence of
subsequent recurrence within the mapped basin.
The false-negative rate (FNR) was calculated by using
the following formula:
½FNRZFN=ðTPþ FNÞ
Table 1 The characteristics of the 127 patients.
Characteristic No. of patients (%)
Sex
Female 64 (50.4%)
Male 63 (49.6%)
Age, y [median (range)] 63.7 (6e87)
<55 29 (22.8%)
55e65 29 (22.8%)
>65 69 (54.4%)
Pathology
ALM 90 (70.8%)
NM 19 (15.0%)
SSM 11 (8.7%)
Other 7 (5.5%)
Location
Upper extremity 14 (11.0%)
Lower extremity 100 (78.8%)
Head and neck 4 (3.1%)
Trunk and back 9 (7.1%)
T stage (Breslow thickness)
T1 (0e1 mm) 12 (9.4%)
T2 (1.01e2 mm) 33 (26.0%)
T3 (2.01e4 mm) 38 (30.0%)
T4 (>4 mm) 36 (28.3%)
Unknown 8 (6.3%)
Ulceration
Yes 52 (41.0%)
No 67 (52.7%)
Unknown 8 (6.3%)
Clark level
IeIII 15 (11.8%)
IVeV 106 (83.5%)
Unknown 6 (4.7%)
SLNB
Positive 44 (34.6%)
Negative 83 (65.4%)
ALM Z acral lentiginous melanoma; NM Z nodular melanoma;
SLNB Z sentinel lymph node biopsy; SSM Z superficial
spreading melanoma.
Figure 1 Results of sentinel lymph node biopsy (SLNB) and
complete lymph node dissection (CLND) for SLNB-positive pa-
tients. Patients with stage T3 or T4 melanoma have a higher
rate of SLNB positivity, compared to patients with stages T1 or
T2. The CLND results reveal additional positive lymph nodes for
all T stages.
SLNB for melanoma in Taiwan 417in which the FNR is the number of patients with negative
SLNB whose melanoma recurs divided by the sum of the
number of patients with positive SLNB (with and without
recurrence) and patients with negative SLNB whose mela-
noma recurs.11 The SLNB failure rate was calculated as the
percentage of patients with nodal recurrence in the same
basin that had been negative at the initial pathologic
evaluation.15
Statistical information
Continuous data are presented as the median with range,
whereas categorical data are presented as the number and
percentage. The overall survival (OS) time was defined as
the period from the date of the tumor excision to the pa-
tient’s death, the last follow-up assessment, or the data
cut-off point. The DFS was defined as the period from the
date of tumor excision to recurrence, the patient’s death,
the last follow-up assessment, or the data cut-off point.
Survival was analyzed by using the KaplaneMeier method.
Univariate analysis was performed by using the Cox pro-
portional hazard model to identify prognostic factors of
survival. To avoid missing potential significant factors,
variables with a p value < 0.10 in the univariate analysis
were further analyzed by using multivariate analysis. A
two-sided statistical test was used for analysis. Statistical
analyses were performed by using SPSS software (version
17.0; SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics
There were 132 consecutive patients with clinically node-
negative cutaneous melanoma who underwent wide exci-
sion (or amputation) and SLNB. The SLN detection rate was
100% by lymphoscintigraphy. During surgery, 127 of 132
(96.2%) patients had a successful SLNB. There were 63 men
and 64 women among the 127 patients who received suc-
cessful SLNB. The median age of the patients was 63.7 years
(range 6e87 years). A total of 90 (70.9%) patients had ALM
and 100 (78.7%) patients had a primary site located on the
lower extremities. Table 1 summarizes the patients’
characteristics.
SLNB results
Forty-four patients had a positive SLNB; hence, the SLNB
positive rate was 34.6%. The positive rate for stage T1 was
25.0% (3 of 12 patients); stage T2, 12.1% (4 of 33 patients);
stage T3, 44.7% (17 of 38 patients); and stage T4, 50.0% (18
of 36 patients). The positive rate for additional metastatic
lymph nodes by further CLND for stage T1 was 33.3% (1/3);
stage T2, 25.0% (1/4); stage T3, 23.5% (4/17); and stage T4,
27.8% (5/18) (Fig. 1).
Clinicopathological prognostic factors of DFS
The median length of DFS was 51.5 months and the esti-
mated 5-year DFS rate was 44.5% in 127 patients with node-
418 C.-E. Wu et al.negative cutaneous melanoma who had a successful SLNB.
Univariate analysis revealed that male sex, a Breslow
thickness greater than 2 mm, ulceration, Clark’s level IV/V,
and positive lymph nodes were associated with a poorer DFS
prognosis (Table 2). A Breslow thickness greater than 2 mm
was the only significant independent prognostic factor of
DFS, as determined by multivariate analysis [hazard ratio
(HR), 3.421; p Z 0.005]. The Clark’s level and ulceration
were confounded by the Breslow thickness and were not
significant prognostic factors, as determined by multivar-
iate analysis.
Clinicopathologic prognostic factors of OS
The median length of OS was 90.9 months and the esti-
mated 5-year OS rate was 59.8% in the 127 patients with
node-negative cutaneous melanoma who received a suc-
cessful SLNB. Univariate analysis revealed that an age
greater than 65 years, male sex, nonacral melanoma, a
Breslow thickness greater than 2 mm, and ulceration were
associated with a poorer OS prognosis (Table 3). A Breslow
thickness greater than 2 mm (HR, 4.435; p Z 0.002), non-
acral melanoma (HR, 3.048; pZ 0.001), and an age greater
than 65 years (HR, 2.819; p Z 0.036) were independent
prognostic factors of OS, as determined by multivariate
analysis. Ulceration tended to be a prognostic factor of OS
(HR, 1.920; p Z 0.067), whereas male sex was not aTable 2 Univariate and multivariate analyses of clinicopatholog
patients.
Factor Univariate analysis
HR (95% CI) p
Age
<55 0.801 (0.369e1.738)
55e65 1
>65 1.383 (0.743e2.576)
Sex
Female 1
Male 1.954 (1.173e3.254)
Type
ALM 1
Other 1.664 (0.985e2.811)
Location
Extremities 1
Other 1.397 (0.664e2.941)
Breslow thickness
2 mm 1
>2 mm 5.422 (2.622e11.211) <
Ulceration
Yes 2.992 (1.742e5.138) <
No 1
Clark’s level
I/II/III 1
IV/V 3.647 (1.133e11.744)
LN status
Negative LN 1
Positive LN 1.610 (0.971e2.668)
ALM Z acral lentiginous melanoma; CI Z confidence interval; HR Zsignificant prognostic factor, as determined by multivariate
analysis.
False-negative sentinel lymph nodes
During a median follow-up of 36.6 months (mean, 44.8
months; range, 1.0e136.4 months), 13 of 83 patients with
negative SLN had clinically positive nodes within the map-
ped basin. The overall SLNB failure rate and FNR were
15.7% and 22.8%, respectively. The SLNB failure rate for
stage T1 was 0% (0 of 12 patients); stage T2, 6.1% (2 of 33
patients); stage T3, 7.9% (3 of 38 patients); and stage T4,
22.2% (8 of 36 patients). The SLNB failure rate increased as
the T stage increased and was significantly higher at stage
T4 than at stages T1eT3 (OR, 8.640; pZ 0.001). Compared
to patients with TP SLN, patients with FN SLN had a
significantly poorer DFS (pZ 0.001); however, there was no
difference between the groups in OS (p Z 0.262) (Figs. 2
and 3). The difference in DFS was maintained after
adjusting for the Breslow thickness (adjusted HR, 3.167;
p Z 0.001).
Discussion
In this retrospective study, the SLNB positive rate was
34.6% in 127 Taiwanese patients who received SLNB. Acral
lentiginous melanoma was furthermore the most commonical factors associated with disease-free survival (DFS) in 127
Multivariate analysis
HR (95% CI) p
0.575
0.307
1
0.010 1.397 (0.792e2.466) 0.249
1
0.057 1.562 (0.882e2.766) 0.126
0.379
1
0.001 3.421 (1.459e8.024) 0.005
0.001 1.625 (0.871e3.030) 0.127
1
1
0.030 1.677 (0.483e5.821) 0.415
1
0.065 0.951 (0.540e1.676) 0.863
hazard ratio; LN Z lymph node.
Table 3 Univariate and multivariate analyses of clinicopathological factors associated with overall survival (OS) in 127
patients.
Factor Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Age, y
<55 2.031 (0.705e5.847) 0.189 1.299 (0.414e4.075) 0.654
55e65 1
>65 3.333 (1.286e8.636) 0.013 2.819 (1.072e7.416) 0.036
Sex
Women 1 1
Men 2.160 (1.172e3.980) 0.014 1.539 (0.784e3.020) 0.210
Type
ALM 1 1
Other 2.289 (1.271e4.122) 0.006 3.048 (1.551e5.990) 0.001
Location
Extremities 1
Other 1.515 (0.705e3.255) 0.287
Breslow thickness
2 mm 1
>2 mm 5.684 (2.479e13.036) <0.001 4.345 (1.841e10.255) 0.002
Ulceration
Yes 3.314 (1.768e6.211) <0.001 1.920 (0.956e3.854) 0.067
No 1 1
Clark’s level
I/II/III 1
IV/V 2.067 (0.638e6.700) 0.226
LN status
Negative LN 1
Positive LN 1.463 (0.814e2.629) 0.204
ALM Z acral lentiginous melanoma; CI Z confidence interval; HR Z hazard ratio; LN Z lymph node.
SLNB for melanoma in Taiwan 419type of melanoma with more than one-half of all patients
having a Breslow thickness greater than 2 mm. During the
follow-up period, 13 of 83 patients with a negative SLN
developed regional nodal recurrence. The resultant SLNB
failure rate was 15.7% and the FNR was 22.8%. Compared
to patients with TP SLN, patients with FN SLN had aFigure 2 Comparison of disease-free survival (DFS) in the
true-negative (TN) group, the true-positive (TP) group, and the
false-negative (FN) group. The DFS is significantly shorter in the
FN group than in the TP group (p Z 0.001). SLN Z sentinel
lymph node.significantly unfavorable DFS, but there was no difference
between the two groups in the OS. To the best of our
knowledge, this is the first report concerning FN SLN in
Asia.
The standard of care for the treatment of clinically
node-negative melanoma has been SLNB. However, fewFigure 3 The comparison of the overall survival (OS) in the
true-negative (TN) group, the true-positive (TP) group, and the
false-negative (FN) group. There is no significant difference
between the FN and TP groups in OS (p Z 0.262).
420 C.-E. Wu et al.studies have examined SLNB in non-Caucasian populations.
Studies performed in Japan have demonstrated SLNB-
positive rates ranging from 21.2% to 41.8%.16e19 Hence,
the overall SLNB positive rate of 34.6% in our study is
consistent with the findings from studies performed in
Japan, but it is higher than rates reported in studies
involving Caucasian populations.10,11 This is because pa-
tients in our study had thicker tumors. Tumor thickness is a
significant independent predictor of SLN metastasis.20 In
Asia, ALM is the most common type of melanoma. It
accounted for approximately 70% of all tumors in our study.
Bradford et al7 performed a study of ALM in the United
States and found that ALM was associated with the highest
tumor thickness, compared to all other cutaneous mela-
nomas. In a comparison of ALM among different races,
Asians were found to have a higher ALM thickness,
compared to other racial groups.7 Therefore, pathologic
subtype and ethnicity seem to play an important role in
cutaneous melanoma.
In the present study, we found that prognostic factors
for OS were tumor thickness, an age greater than 65 years,
nonacral melanoma, and possibly ulceration. Melanoma
thickness and ulceration are the most important predictors
of survival in the AJCC melanoma staging database of
localized melanoma.21,22 It is unclear why ALM is associated
with a better prognosis in our patients since this type of
melanoma is associated with a poorer prognosis, relative to
other melanoma subtypes.7 However, a previous study in
Taiwan also reports that ALM is an independent prognostic
factor for better OS, as determined by multivariate anal-
ysis.23 One possible explanation is that the most common
subtype of nonacral melanoma in our study and in a pre-
vious study23 was nodular melanoma (NM). In Taiwan, SSM
(which is associated with a better prognosis than either ALM
or NM) accounts for only a small proportion of nonacral
melanoma cases.
The overall FNR and SLNB failure rate in our study was
22.8% and 15.7%, respectively. A meta-analysis of 71 pub-
lished studiesdwhich included 25,240 patients with mela-
noma who underwent SLNBdreports an average FNR of
12.5% and a SLNB failure rate of 3.4%.11 The higher FNR and
SLNB failure rate in our study may be explained by the
greater Breslow thickness of the melanoma and by the fact
that none of the patients received high-dose adjuvant
interferon-a. Valsecchi et al11 previously reported that the
SLNB failure rate increased as the Breslow thickness
increased. This probably is related to the more aggressive
tumor behavior of a thicker melanoma. High-dose adjuvant
interferon-a can prolong DFS and may decrease regional
recurrence.24 In addition, Scoggins et al10 report that pa-
tients with FN SLN have a statistically poorer DFS (but not
OS) than patients with TP SLN. We similarly found that pa-
tients with FN SLN had a significantly unfavorable DFS (but
no difference in OS), compared to patients with TP SLN.
Further investigation that includes clinical features10 and
genetic alternations25 is warranted to understand the tumor
biology of cutaneous melanoma in patients with FN SLN.
The current study has several limitations. First, because
of its retrospective single-institution nature, some bias may
have been introduced because of incomplete data records.
Second, none of our patients received high-dose adjuvant
interferon-a, which has been shown to significantly improvethe DFS of patients with high-risk melanoma. However, the
results of interferon-a concerning OS have been less
conclusive.26,27 Third, the status of SLNBs was determined
by using H&E staining and/or HMB-45 staining, rather than
by the more sensitive reverse transcriptase polymerase
chain reaction (RT-PCR) assay. The RT-PCR assay is more
sensitive for detecting occult metastases, compared to
routine histology.28 However, the prognostic significance of
a positive RT-PCR test remains uncertain.29,30 Fourth, the
mitotic rate was not routinely assessed in our patients.
Therefore, we were unable analyze the prognostic signifi-
cance of the mitotic rate, which is a prognostic factor
specified in the AJCC staging criteria.12
In conclusion, the Breslow thickness is the most impor-
tant prognostic factor for DFS and OS in Taiwanese patients
with clinically node-negative cutaneous melanoma who
receive primary surgery and SLNB. These prognostic factors
are similar to those used in melanoma-prevalent countries.
The FN SLNB affected the patients’ DFS, but not their OS
outcome. Therefore, it is important to identify and closely
monitor patients at risk for nodal recurrence after a
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